- Details
- Rashid Sayyid and Zach Klaassen discuss the publication on genomic classifier performance in intermediate-risk prostate cancer, focusing on the results of the NRG Oncology/RTOG 01-26 randomized Phase 3 trial. The study explores the use of the Decipher 22-gene genomic classifier in risk stratification, outperforming other common risk classification systems for prostatectomy and pre-treatment biopsy...
|
- Details
- Ashley Ross and Jim Hu discuss the use of genomic classifiers, specifically the Decipher Genomic Classifier, in the management of localized prostate cancer. They review its performance in larger datasets and its association with prostate cancer outcomes. The conversation also delves into the use of the Decipher Prostate Biopsy Test in men with favorable risk disease undergoing conservative managem...
|
- Details
- Preston Sprenkle and Randy Vince join Ashley Ross to discuss active surveillance and the benefits of risk stratification for localized prostate cancer. They collectively emphasize the importance of monitoring cancer closely and intervening with curative intent if it becomes aggressive while minimizing morbidity and improving quality of life. Dr. Vince highlights the Michigan Urological Surgery Imp...
|
- Details
- Katie Murray and Anne Lizardi-Calvaresi discuss a clinical pathway approach for using the Decipher prostate cancer genomic classifier. Reviewing the level-one evidence described in the NCCN guidelines, they discuss best practices as clinicians integrate prostate cancer genomic classifiers into the care of their patients. They highlight how the test is integrated into the workflow for patient navig...
|
- Details
- Alicia Morgans and Ashley Ross discuss how the Decipher prognostic biomarker prostate classifier is being integrated into phase II and III clinical trials, a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment. The pair highlights dat...
|
- Details
- David Morris joins Ashley Ross in a conversation on genomics in prostate cancer specifically, in the unfavorable intermediate-risk patient. Drs Morris and Ross highlight the use of genomics in decision-making when considering what the best treatment option is for this group of individuals. They are particularly interested in determining if any of these intermediate-risk patients might actually be...
|
- Details
- Alan Dal Pra joins Alicia Morgans in a discussion on the prognostic and predictive performance of the 24-gene Post-Operative Radiation Therapy Outcome Score, the PORTOS signature in the phase 3 randomized clinical trial assessing dose escalation after radical prostatectomy, the SAKK 09/10 trial. The SAKK 09/10 was a multicenter, randomized phase III trial performed across 24 centers in Switzerland...
|
- Details
- Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...
|
- Details
- Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers....
|
- Details
- Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk non-met...
|
